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7 in group D; P , 0.0001, analysis of variance], as did theirInadequate diagnosis and therapy of arterial hypertension as
corresponding LVMs [132 6 27 g/m2 body surface area (BSA),causes of left ventricular hypertrophy in uremic dialysis pa-
156 6 26, 201 6 51, and 200 6 36; P , 0.0001]. There weretients.
also differences in dialytic age, which was significantly longerBackground. Left ventricular hypertrophy (LVH) is highly
in group A patients (109 6 54 months), who also tended toprevalent in the dialyzed population, possibly because of inade-
have higher, although not significantly higher, Kt/Vurea values.quate diagnosis and therapy of arterial hypertension. The pur-
No differences, however, were detected among the groups aspose of this study was to ascertain the adequacy of our approach
far as type, dosages, and number of antihypertensive drugsin correctly identifying and treating arterial hypertension in
given to each individual patient.our dialysis center.
Conclusions. The high prevalence of LVH in the dialysisMethods. Fifty-five dialyzed uremics were studied by con-
population might be the result of inadequate diagnosis andtinuous ambulatory blood pressure (BP) monitoring, which
therapy of arterial hypertension. Arterial hypertension, in fact,started before a single hemodialysis (HD) session, continued
was insufficiently treated in our dialysis center, since patientsfor 24 hours after HD ended, and was repeated for 15 minutes
with varying degrees of severity of both arterial hypertensionbefore the beginning of the next HD. Clinical pre-HD and
and LVH were kept on antihypertensive therapy of similarpost-HD routine BP measurements taken the month preceding
strength. Undertreatment may have resulted from not havingBP monitoring were retrieved, and echocardiography was per-
recognized and/or from having underestimated the severity offormed.
arterial hypertension since some clinical BPs were measuredResults. LVH was present in 46 out of 55 patients, and clini-
incorrectly. Reluctance to use more aggressive antihyperten-cal pre-HD arterial hypertension was present in 36 out of 55.
sive therapy might also result from the deceptive feeling ofThere were discrepancies between clinical and monitored BPs,
“normalized” BP that one has following volume unloading withmostly concerning diastolic pre-HD BP since BP readings were
dialysis. This causes both the BP to run out of control betweenlower than monitored BP records (P , 0.0002). Although both
dialyses and LVH to worsen.clinical and monitored BPs bore strong direct correlations with
the left ventricular mass (LVM), the closest correlations were
those for monitored BP. Four groups of patients were identified
by BP monitoring: group A (N 5 14), with persistently normal Left ventricular hypertrophy (LVH) is the single
BP, and group D (N 5 13), with persistently supranormal BP strongest predictor of adverse cardiovascular eventslevels. There were also two other groups (group B, N 5 19;
[1, 2]. Besides the subject’s age, arterial hypertensionand group C, N 5 9), whose BP values were high before HD,
is the closest clinical correlate to LVH both in uremicnormalized after HD, and then increased again either soon
after HD (group C) or later on following HD (group B). patients and in the general population as well [3, 4].
Monthly averaged clinical pre-HD mean BP values differed Over the last few years, the increased use of powerful
significantly among the four groups [91 6 10 (SD) mm Hg in antihypertensive drugs has resulted in a reduced preva-group A, 101 6 7 in group B, 106 6 6 in group C, and 106 6
lence of arterial hypertension and a concomitant decline
in LVH and cardiovascular mortality in the general pop-
ulation [5]. The cardiovascular death rate, however, re-Key words: antihypertensive therapy, LVH, chronic uremia, cardiovas-
cular mortality, blood pressure. mains persistently elevated in dialysis patients [6, 7],
while both arterial hypertension and LVH are still highlyReceived for publication May 26, 1999
prevalent [8, 9]. Studies on dialysis patients, however,and in revised form January 25, 2000
Accepted for publication February 2, 2000 have shown that LVH is potentially reversible when a
good dialysis regimen is combined with aggressive anti-Ó 2000 by the International Society of Nephrology
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hypertensive treatment [10]. Thus, inadequate diagnosis 2.5 to 3.5, calcium from 2.5 to 3, and bicarbonate from
33 to 35 mEq/L.and therapy of arterial hypertension may be likely causes
The ideal “dry” body weight was established accordingfor LVH being so highly prevalent in uremic patients.
to clinical and instrumental diagnostic procedures, asThe purpose of this study was to ascertain the adequacy
previously reported [13]. The subjects’ diets consisted ofof our current approach in identifying and treating arte-
1.1 to 1.2 g of protein content per day, with unrestrictedrial hypertension in our center. In this study, we have
cooking salt but with no canned or salty-tasting foods.collected indicators that may help explain why arterial
If, however, the patients experienced excessive thirst orhypertension in dialysis patients might remain both un-
disproportionate interdialytic body weight gain (IWG),derdiagnosed and undercured.
a salt-restricted diet with no more than 4 g of salt per
day was prescribed until the symptoms subsided.
METHODS Most patients were treated with recombinant human
Patient selection erythropoietin (rHuEPO) aimed at keeping their predi-
alysis hemoglobin (Hb) level at approximately 10 g/dL.Patients in this study were recruited from among 130
They were also administered oral or intravenous cal-patients already undergoing treatment at our dialysis
citriol and calcium-containing salt phosphate binders.center. The main inclusion criterion was the availability
Some of them had already been on treatment with oneof an optimal chest acoustic window to allow a state
or more antihypertensive drugs for varying periods ofof the art echocardiogram to be made. Other inclusion
time in order to control arterial hypertension. The drugscriteria were to have been enrolled in a regular renal
included the angiotensin-converting enzyme (ACE) in-replacement treatment program for at least six months
hibitor lisinopril at dosages ranging from 2.5 mg on alter-and a willingness to participate in the study. The exclu-
nate days to 20 mg a day, the calcium channel blockersion criterion was an existence of concurrent illness, such
nifedipine 30 mg a day, and the b blocker atenolol upas chronic inflammatory diseases and cancer, besides
to 50 mg a day. Therapy was given on a daily basiswell-known causes of LVH except for arterial hyperten-
regardless of the dialytic schedule of each individualsion (such as diabetes, coronary arterial disease, signifi-
patient. Sera were routinely tested at least monthly aftercant valvular regurgitation, congestive heart failure, and
a long interdialysis interval to measure predialysis Hb,severe uremic anemia) [11]. Patients were also excluded
urea, and circulating parathyroid hormone (iPTH).
if they had a frequent recurrence of intradialytic hypo-
tension, defined according to criteria reported elsewhere Procedures and study protocol
[12]. All of the clinical blood pressure (BP) measurements
After these inclusion and exclusion criteria were met, obtained by mercury sphygmomanometer, as well as the
the records of each patient were retrieved, and only body weight measurements recorded by the nurses be-
subjects not having undergone major changes (65%) in fore and after the 12 hemodialysis (HD) sessions done
their prescribed ideal “dry” body weight or modifications the month preceding the study, were retrieved and stored
in their antihypertensive regimen over the previous three for subsequent statistical analyses. The number and dos-
months were chosen. Thus, the final study group con- ages of antihypertensive drugs used over the previous
sisted of 55 patients, 24 women and 31 men, whose ages three-month period were also recorded.
ranged from 24 to 74 years and who had already been Continuous ambulatory BP monitoring took place in
on renal replacement therapy for at least six months. the morning before a midweek interdialysis day. Before
Renal diseases causing end-stage renal failure were: glo- the fistula needle was inserted, each patient was equipped
merulonephritis in 20 patients, adult polycystic kidney with a portable BP monitor (Spacelab 90207) in order
disease in 9, hypertensive nephrosclerosis in 9, interstitial to provide BP measurements over the following 24 hours.
nephropathies in 10, other causes or unknown etiologies Further BP monitoring beyond this limit was ruled out
in 7 patients. by the unwillingness of most of the subjects to wear the
All subjects were on dialysis three times per week with monitor for a long period of time. Monitored BP records
standard bicarbonate dialysis or high-flux hemodiafiltra- were taken every 30 minutes during conventional waking
tion. Treatment lasted from 4 to 4.5 hours and the dia- hours (until 8 p.m.) and every 60 minutes during evening
lyzer surface area ranged from 1.3 to 1.8 m2; both of these and sleeping hours (from 8 p.m. to 8 a.m.). Just before
were prescribed on an individual basis in an attempt to the following HD, which took place 48 hours later, the
obtain a Kt/Vurea $1.2. The intradialytic body weight patients rested supine in their beds, and their BP was
decrease was individually modeled by controlled ultra- again monitored every 5 minutes for 15 minutes. These
filtration with the aid of computer-assisted dialysis ma- measurements were averaged and were considered rep-
chines. The solute concentrations in the dialysis bath resentative of the monitored BP levels actually present
at that time.were as follows: sodium from 139 to 141, potassium from
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Echocardiography was arranged and performed in all 9 (57 to 100) mm Hg, while postdialysis BPs were 135 6
16 (101 to 180) and 77 6 9 (58 to 100) mm Hg. Overall,subjects on a midweek interdialysis day, usually within
a week before or after ambulatory BP monitoring. The the BP decreases induced by HD were significant for
both systolic (t 5 4.55, P , 0.0001) and diastolic (t 5measurements included the end systolic (ESD) and dia-
stolic (EDD) diameters of the left ventricle, the interven- 3.38, P , 0.0013) values. The decreases in body weight
from 64.3 6 12.3 kg before to 61.8 6 12 kg after dialysestricular septum (IVS) thickness, the thickness of the pos-
terior left ventricular wall (PW), and the diameter of the were also significant (t 5 23.6, P , 0.0001).
Echocardiography performed during the week beforeleft atrium (LA). The criteria for adequacy of collection,
reading, and reproducibility of our echocardiographic or after test-HD revealed that 46 out of 55 patients in
the study had LVH.measurements have been reported elsewhere [11].
Pretest-HD monitored BPs were systolic 144 6 19 (95
Definitions, calculations, and statistics to 182) mm Hg, which were not significantly different
from the monthly averaged sphygmomanometrically col-The upper limits for normal sphygmomanometric sys-
tolic/diastolic and mean BPs (mBPs) were 140/90 and lected BPs (t 5 1.41) and diastolic 85 6 12 (64 to 124)
mm Hg, which were slightly but significantly higher (15.3106.6 mm Hg, as already set forth by the JNC VI [14]. All
subjects having BPs above these limits were considered mm Hg; CI, 2.6 to 7.9; t 5 4.01, P , 0.0002). There were
close correlations for both systolic (Rp 5 0.74, P ,hypertensive. Likewise, the thresholds for normality of
the ambulatory-monitored BP were 133/81 and 98.3 mm 0.0001) and diastolic BPs (Rp 5 0.58, P , 0.0001) be-
tween the two sets of data as well as between each ofHg, as already established by Staessen et al [15]. Classifi-
cation of patients as “dippers” and “nondippers” was these BP measurements and LVM. These relationships
were Rp 5 0.54, P , 0.0001 (for monitored systolic);made according to the criteria issued by the same group
[16]. Rp 5 0.51, P , 0.0001 (for manual systolic); Rp 5 0.46,
P 5 0.0004 (for monitored diastolic); and Rp 5 0.38,Blood pressure responsiveness to HD was defined as
P 5 0.004 (for manual diastolic).a greater than 5% decrease of the mBP according to the
Classification of the patients as hypertensive or nor-criterion proposed by Sullivan et al [17].
motensive on the basis of predialysis systolic BPs re-The presence or absence of LVH was defined on the
vealed that according to the ambulatory BP monitoringbasis of a calculated [18], indexed left ventricular mass
criteria (cut-off systolic BP 5 133 mm Hg), 45 out of 55(LVM) $120 g/m2/body surface area (BSA) [11]. The
patients (82%) were hypertensive, while according tofractional shortening (% FS) of the LV was calculated
the JNC VI criterion (cut-off 5 140 mm Hg) 36 out ofas EDD-ESD/EDD 3 100.
55 (65%) were hypertensive (Table 1). Classification ofData are presented as mean 6 SD and ranges. The
patients using these two criteria was not significantlyStudent’s t-test was used for comparison between two
discordant (k 5 0.41, P , 0.001), although there wasgroups. Comparisons among groups at any given time
disagreement as far as 13 patients were concerned.were made by analysis of variance (ANOVA). Signifi-
Eleven out of 13 of these patients were normotensivecant differences in measurements within a single group
according to the nurses but were hypertensive accordingor between groups over time were assessed by ANOVA
to the BP monitor (Table 1). Their corresponding BPfor repeated measures. When the F test was significant,
values were 129 6 8 (108 to 139) and 142 6 8 (133 toSheffe`’s post hoc test for multiple comparisons was calcu-
157) mm Hg, which differed significantly (t 5 5.18, P 5lated. The significance of associations between two vari-
0.0004).ables were assessed by calculating the Pearson’s rank
When the same analyses were made for diastolic BPs,correlation coefficient (Rp), while linear regression was
it appeared that there were 33 out of 55 (60%) patientscalculated by the least-squares method. Significant dif-
who were hypertensive according to the BP monitor andferences between regression lines were assessed by the
only 7 out of 55 (13%) who were hypertensive accordinganalysis of covariance (ANCOVA). Frequencies among
to the manual BP measurements (Table 1). Classificationgroups were compared by the x2 test, while Fisher’s exact
of patients by these two criteria was not concordant (k 5test was used when appropriate. Concordance between
0.11; P 5 NS). The main disagreement between the twocategorical variables was assessed by calculating the “k”
classifications consisted of 27 patients who were classifiedCohen’s coefficient of concordance.
as normotensive by the nurses and who proved to be
hypertensive by the BP monitor. Diastolic BPs for these
RESULTS patients according to the two methods were 82 6 5 (70
The average BP measurements collected by nurses to 89) and 91 6 9 (81 to 124) mm Hg, respectively, which
before and after the 12 hemodialyses performed the were significantly different (t 5 6.29, P , 0.0001).
month preceding the study were predialysis systolic, When the same analyses were made for mean BP
values, there were 14 (25%) concordant normotensive142 6 15 (range 102 to 165) mm Hg, and diastolic, 80 6
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Table 1. Patient classification
Predialysis Postdialysis
Portable monitor Sphygmomanometry Systolic BP Diastolic BP Mean BP Systolic BP Diastolic BP Mean BP
Normotensive Normotensive 8 (14%) 21 (38%) 14 (25%) 29 (53%) 36 (65%) 37 (68%)
Normotensive Hypertensive 2 (4%) 1 (2%) 0 12 (22%) 0 2 (4%)
Hypertensive Normotensive 11 (20%) 27 (49%) 23 (42%) 3 (5%) 14 (26%) 8 (14%)
Hypertensive Hypertensive 34 (62%) 6 (11%) 18 (33%) 11 (20%) 5 (9%) 8 (14%)
Classification of 55 dialyzed uremics as normotensives or hypertensives was according to the pre- and postdialysis blood pressure (BP) levels measured with two
different methods of BP measurement entailing different cut-off limits for discriminating normal from supranormal BP levels.
patients, 18 (33%) concordant hypertensive patients, and
23 patients (42%) who were considered normotensive
by the nurses and hypertensive by the BP monitor (Table
1). The corresponding monitored and manual BP levels
for these 23 patients were 108 6 7 (99 to 124) and 99 6
5 (88 to 105) mm Hg, which differed significantly (t 5
5.8, P , 0.0001). Furthermore, the LVM of these patients
was 174 6 43 (112 to 263) g/m2 BSA, which was signifi-
cantly higher than concordant normotensives [132 6 27
(84 to 191) g/m2 BSA, P , 0.01], but similar to those of
concordant hypertensives [189 6 39 (128 to 267) g/m2
BSA, P 5 NS].
Post-test-HD monitored diastolic BPs were 76 6 12
(57 to 110) mm Hg, which were not significantly different
Fig. 1. Correlation between levels of mean blood pressure measuredfrom the monthly averaged sphygmomanometrically col-
24 hours after the end of hemodialysis (HD) with a portable monitorlected BPs, and systolic BPs 126 6 19 (96 to 179) mm in 55 uremic patients and the corresponding values for the indexed left
Hg, which were significantly lower [29.4 (CI, 4.95 to ventricular mass (LVM) in the same subjects. The closed circles (d)
indicate patients on antihypertensive therapy for at least six months13.85) mm Hg, t 5 4.24, P , 0.0001)].There were close
(r 5 0.63; P , 0.0001).correlations for both diastolic (Rp 5 0.613, P , 0.0001)
and systolic BPs (Rp 5 0.567, P , 0.0001) between the
two sets of data. Furthermore, there were significant cor-
relations between these BP measurements and the LVM. between LVM and mean BP recorded at the 24th hour
Analyzing the classification of patients, which was (Fig. 1 shows this relationship).
made on the basis of the criteria underlying the two Scrutiny of the monitored BP records of each individ-
methods of BP measurement, revealed that there were ual patient revealed that the patients’ BP values behaved
no statistical discordances between them (Table 1). differently over time, thus allowing us to identify four
After filtering out the patients who were discordantly distinct groups of patients (Fig. 2). One group (group
classified according to the two methods of BP measure- A, N 5 14) had persistently normal monitored BP, and
ment, all of the correlations previously found between another one (group D, N 5 13) had persistently su-
the different sets of BP measurements strengthened pranormal BP levels. There were also two other groups
greatly. This fact was impressive as far as systolic BP whose BP levels were high before HD, normalized after
values before dialysis were concerned in that the BP HD, then increased again, either soon after HD (group
measured by one method closely approached the identity C, N 5 9) or later on following HD (group B, N 5 19).
to the BP measured by the other (N 5 42, Rp 5 0.84, Statistical analysis made by ANOVA for repeated
graph not shown). measures confirmed that there were indeed differences
Test HD procedures were carried out in all cases with among these four groups over the entire time frame of
observation (F 5 83.46, P , 0.0001). This means thatno technical inconvenience and HD proved to be un-
eventful in all subjects. differences were detectable between two or more than
two groups at any given time (F 5 37.29, P , 0.0001).Preliminary statistical analyses revealed that there
were correlations between each set of systolic, diastolic, Before HD, there were differences between group A
and group B (t 5 9.36, P 5 0.0001) and between groupand mean monitored BP values recorded at any given
time and the LVM. The ANCOVA analysis, however, B and group D (t 5 4.4, P 5 0.0001).
Overall, the BP behavior in group A changed signifi-demonstrated that the strongest correlation was the one
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A and B and between groups C and D were not remark-
able. These differences in LVMs were mostly accounted
for by differences in the PW and in the IVS, and by
slight but insignificant differences in the EDD. No other
relevant differences in the cardiac measurements were
found, although the LA tended to be larger in groups
C and D, and the % FS of the LV tended to be lower in
group C. Other relevant differences were those regarding
dialytic age, which was significantly higher in group A
patients, who also had a tendency for higher Kt/Vurea
values (Table 2).
No other statistical differences were detectable among
the groups as far as serum PTH and Hb levels were
concerned or regarding the weekly average dose of
rHuEPO administered to each group.
With regards to the use of antihypertensive drugs, theFig. 2. Average levels for the mean BP measured by a portable monitor
for four groups [group A (d), N 5 14; group B (r), N 5 19; group C number of subjects on antihypertensive therapy differed
(m), N 5 9; group D (j), N 5 13] of dialyzed uremics over a period among the four groups (Table 2). The main difference
that included a single dialysis treatment (Uf-HD). BP levels were differ-
(Fisher’s P 5 0.0019), however, was found betweenent over time in these four groups (F 5 83.46; P , 0.0001 by ANOVA),
since differences were detectable between two or more than two groups group A, where 43% of the patients were taking drugs,
at any given time (F 5 37.29, P , 0.0001). and group D, all of whom were already on antihyperten-
sive treatment. No other differences were found concern-
ing time elapsed since the beginning of therapy, number
of drugs given to each treated patient, number of patientscantly (F 5 3.7, P 5 0.0007). It tended to decrease slightly
taking ACE inhibitors, or as far as ACE inhibitor dos-but continuously from before HD onward, and by the
ages were concerned (Table 2).12th hour had become significantly lower than before
HD (P , 0.01). From then on, however, it started to
gradually increase. By 48 hours, it no longer differed in DISCUSSION
comparison with those recorded before HD. One of the reasons for the high prevalence of arterial
In both groups B and C, BP during HD decreased to hypertension in dialysis patients might be in the way
the same extent (t 5 7.62, P , 0.001, and t 5 5.46, P , physicians treat arterial hypertension once it has been
0.001, respectively). From that point onward, however, diagnosed. Classifying one as a hypertensive subject is
the BP behavior between the two groups diverged. Al- a difficult task, since the BP threshold that antihyperten-
though the BP level in group B remained nearly unvaried sive treatment should be started at is quite discretional
until 24 hours, it was still high when remeasured before unless definite, attendant end-organ damage is docu-
the next HD. In group C, the BP started rising as of the mented [19]. The issue is rendered even more compli-
fourth hour (P 5 0.01) after the end of HD. BP levels cated by the intrinsic variability of BP over time [20], the
in group D tended to decrease from the before to after discrepancies between the methods of BP measurements
HD measurements. This decrease, however, was not sig- [20], as well as by common errors in correctly measuring
nificant and even completely disappeared, although the true average BP levels [21].
gradually, afterward. Admittedly, all of these shortcomings inherent to BP
Since analysis of the individual BP behavior allowed management in the general nonuremic population also
us to classify four distinct groups of patients, we were apply to the treatment of arterial hypertension in dialysis
encouraged to further analyze the data and to look for patients. The task is even more difficult in these patients
other differences, if any, that would distinguish these because of the wide BP fluctuations that typically occur
groups. Some of the data taken into consideration are during and between dialyses as a result of the diffusive
listed in Table 2. dialytic procedure and of the manipulations and varia-
There were no differences among the four groups as tions of the extracellular fluid volume (ECFV) [22]. In
far as distribution of etiologies of underlying renal dis- fact, there are great uncertainties regarding the best
eases, gender ratios, or age were concerned. The most method for measuring BP (manual vs. monitored), re-
relevant difference, besides BP levels, that distinguished garding the BP levels that should be considered patho-
the four groups was the LVM (Table 2). LVMs, in fact, logical, and regarding the best time (before dialysis, dur-
were lower in groups A and B than in groups C and D ing dialysis, after dialysis, interdialytic off-day dialysis)
for collecting reliable BP readings [8].(P at least ,0.002), while the differences between groups
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Table 2. Comparisons of demographic, clinical and echocardiographic data for four groups of patients with different BP behaviors during
and between dialysis treatments
Variable Group A Group B Group C Group D Test P value
N 14 19 9 13
Dialytic age months 109654 45635 48644 72646 ANOVA 0.0011
Monthly averaged pre-HD mBP mm Hg 91610 10167 10666 10667 ANOVA 0.0001
Monthly averaged post-HD mBP mm Hg 89610 9668 98 611 10467 ANOVA 0.0016
Dippers/nondippers 6/8 12/7 2/7 7/6 x2 NS
On antihypertensive therapy yes/no 6/8 13/6 7/2 13/0 x2 0.012
On ACE inhibitors yes/no 5/1 12/1 7/0 13/0 x2 NS
One drug/two drugs/three drugs 5/0/1 5/5/3 4/1/2 7/5/1 x2 NS
%IWG kg 4.061.0 4.461.3 4.861.8 3.661.1 ANOVA NS
IVS mm 11.762.4 12.561.7 12.961.4 14.162.5 ANOVA 0.036
PW mm 10.261.4 10.761.9 11.861.2 12.261.9 ANOVA 0.013
EDD index mm/m2 BSA 28.764.2 29.862.6 32.363.8 31.265.3 ANOVA NS
LVMi g/m2 BSA 132627 156626 201651 200636 ANOVA 0.0001
LA index mm/m2 BSA 21.663.9 21.663.3 24.268.2 23.164.1 ANOVA NS
% FS 4266 39 67 35 68 40 66 ANOVA NS
Hb g/dL 10.560.7 9.961.3 9.861.1 9.761.3 ANOVA NS
iPTH pg/ml 2796231 2056157 1666192 1726185 ANOVA NS
Kt/V 1.3360.21 1.1860.17 1.1960.17 1.2060.11 ANOVA NS
rHuEpo dose IU/kg/week 118684 127689 96674 135664 ANOVA NS
Abbreviations are: HD, hemodialysis; mBP, mean blood pressure; ACE inhibitors, angiotensin converting enzyme inhibitors; IWG, interdialytic weight gain; IVS,
interventricular septum; PW, left ventricular posterior wall; EDD, left ventricular end diastolic diameter; LA, left atrium; LVMi, left ventricular mass index; FS, left
ventricular fractional shortening; Hb, hemoglobin concentration; iPTH, intact parathyroid hormone; rHuEpo, recombinant human erythropoietin. Data are given as
mean 6 SD, when appropriate.
Left ventricular hypertrophy is said to be not only the of measurement in that manual measurements were gen-
erally lower than those measured by the monitor. LVMsresult of long-lasting arterial hypertension [4], but also
strongly associated to present or oncoming coronary, of patients who were discordantly classified by the two
methods were more closely correlated to monitoredperipheral, and cerebrovascular diseases [2, 23]. There-
fore, measuring the LV would be an aggregate measure- rather than manual BPs. Thus, on the basis of these
findings, we suspect that a considerable number of pa-ment of the end-organ effects of raised BP, which would
be a less controversial marker of long-lasting arterial tients who were actually hypertensive might have been
erroneously classified as normotensive by the nurses.hypertension than are elusive or questionable spot BP
measurements [19, 24]. This was the reason that we used Such errors in measuring clinical BP levels in dialyzed
uremics are not irrelevant, as one might attribute a falseechocardiographic measurements of the LV together
with a series of clinical and monitored BP data to verify normotensive classification to subjects who are actually
hypertensive, thus possibly causing the link between ar-the soundness of our own criteria for identifying and
treating arterial hypertension. Therefore, we only selec- terial hypertension and LVH to be missed. This may be
relevant if one thinks of the early studies appearing inted patients without well-known LVH-inducing causes,
except for arterial hypertension. This accounts for the the late 1980s, which failed to uncover any relationship
between clinically measured BP and LVH [28, 29].exclusion of patients with diabetes that might have an
independent pro-growth effect on the LVM [25]. One Close scrutiny of the individual BP behavior during
dialysis and over the period between dialyses allowedrelevant finding of our study is the strong, direct associa-
tion between BP and LVM. Such a finding is not new, us to roughly distinguish four groups of patients. The
average dimensions of the internal diastolic left ventricu-as it has already been reported in studies of dialysis
patients [26, 27]. What is surprising is the unprecedented lar diameter and of the LA did not differ significantly
among groups. In previous studies, left atrial dimensionsstrength of the association we found between these two
parameters. Most of our patients were being treated with of dialyzed uremics were strictly correlated to the intra-
vascular volume loads [30, 31], as well as to the totalACE inhibitors, which might have an LVM-lowering
effect, regardless of their hypotensive effects [12]. Thus, blood volume and to the plasma concentrations of the
atrial natriuretic peptide [30]. Thus, it seems unlikelyit is possible that the strong BP-LVM relationship we
found might have been even stronger had the patients that our patients had grossly divergent ECFV levels. In
spite of this, in the face of similar ECFV unloading withnot been undergoing treatment with these drugs.
In our study, absolute values of manual and clinical dialysis, the BP of some patients (namely, those in groups
A and D) remained nearly unaffected, while the BP ofBP levels were closely correlated to each other when dis-
cordant measurements were discarded. However, there others (groups B and C) was greatly lowered. Moreover,
inspection of BP behavior in group A clearly indicateswere too many discrepancies between the two methods
Cannella et al: Arterial hypertension and LVH in uremia266
that HD treatment induced a prolonged BP decrease busy. Therefore, understaffing and huge pressures on
personnel and technicians should be minimized. Carefulthat lasted far beyond the end of volume unloading.
Thus, it appears that the diffusive process inherent to training of the nurses—including occasional confirma-
tion of their ability to collect sphygmomanometric BPthe dialytic treatment might have had a BP-lowering
effect regardless of intravascular volume unloading. It correctly—should also be required [21]. The errors more
frequently affected diastolic than systolic BP. Thus, sys-is impossible to tell to what extent this volume-indepen-
dent hypotensive effect(s) might also have contributed tolic rather than diastolic BP should be used as a reliable
reference BP value, since the former is better at detectingto the BP decrease in groups B and C.
In this study, BP increased considerably in nearly one raised BP levels [21]. Furthermore, since postdialysis BP
readings might be deeply affected by the hypotensivehalf of the patients between dialysis treatments, in spite
of a body weight gain that was quite similar to patients effects induced by the diffusive process, it is probably
wise to rely on predialysis rather than postdialysis BPwhose BP values rarely varied. Differences in individual
BP sensitivity to intravascular volume re-expansion data. The deceptive nature of these data, in fact, might
engender reluctance in prescribing or strengthening hy-might account for this observation [32]. Subjects whose
BP levels had increased were the same ones whose BP pertensive therapy. Furthermore, establishing the dry
body weight on the basis of postdialysis BP in an attemptvalues completely normalized following the dialytic treat-
ment. Thus, these findings strongly support the study by to correct a fictitious ECFV contraction might lead to
the development of chronic hypervolemia and furtherCheigh et al in which BP monitoring unveiled uncon-
trolled arterial hypertension between dialyses in patients worsening of hypertension. Each subject whose predial-
ysis systolic BP is high should probably be consideredalready deemed as having “volume-responsive arterial
hypertension” [22]. hypertensive, no matter how much his or her BP de-
creases from before-to-after dialysis. Except for the fewRegardless of the mechanism(s) causing BP to increase
in some patients during the interdialysis interval, what hours during and after dialysis treatment, in fact, the BP
of these patients remains considerably elevated, whileis remarkable is that this unfavorable BP behavior was
associated with LVH. Furthermore, it is also noteworthy their LVH might worsen relentlessly. From a practical
point of view, therefore, once a frank volume overloadthat the degree of LV overgrowth in these subjects was
roughly inversely related to the amount of time they had has been ruled out, it is probably wise to treat these
patients with drugs or to reinforce their antihypertensiveremained normotensive. However, hypertension-depen-
dent LVH requires some time to develop [2]. Therefore, treatment disregarding the few hours of apparently nor-
mal BP levels they experience.it is likely that the LVH detected in our patients was a
consequence of customary rather than occasional BP Finally, our study has further convinced us of the use-
fulness of echocardiography in correctly diagnosing arte-behavior.
In a previous study of dialysis patients, inadequate rial hypertension. What we have learned is that every
effort should be made to rule out underlying arterialstrength of antihypertensive therapy was thought to be
the reason why neither raised BP levels nor LVH im- hypertension in uremic subjects with seemingly normal
clinical BP and raised LVM. Moreover, periodic echocar-proved satisfactorily under prolonged antihypertensive
therapy [13]. In this study, only a few patients whose BP diography (once or twice a year) [12, 13] would also
provide a useful tool for tailoring and monitoring effec-was high and whose LVM was heavy were left untreated
(Fig. 1). On the other hand, it must also be said that tive antihypertensive therapy and, in dubious cases,
could also provide an objective estimate of the intravas-the treated patients were on antihypertensive therapy of
equal strength in spite of different degrees of severity cular volume load [30].
The last JNC indicates 120/80 mm Hg as the optimalof both arterial hypertension and LVH. The pitfalls dis-
covered by our analysis and the ensuing clinical misjudg- BP [14]. In this study, only 9 out of 55 patients had almost
normal or normalized LVMs (Fig. 1). The predialysisments that can be engendered might collectively account
for our underestimating the severity of the hypertensive systolic BP of these patients was 131 6 19 mm Hg,
ranging from 102 to 148 mm Hg. Thus, a systolic BP lowerdisease.
One limit to this study is that it is, indeed, only a than 148 mm Hg should be the target of antihypertensive
therapy, which is aimed at reversing LVH.single-center study. Should our data be representative
of the difficulties and the pitfalls inherent to the approach Besides BP control, proper dialysis adequacy might
also be relevant when dealing with LVH of hypertensiveof arterial hypertension in dialysis centers worldwide, a
reappraisal of the current approach to this clinical prob- patients on dialysis. It should be noted that all patients
who had normal LVM belonged to group A. This grouplem would be warranted.
First, there were mistakes in the way our nurses mea- had higher dialytic ages, as well as a tendency toward
higher Kt/Vurea values. There may be a link betweensured BP levels. These errors were more frequent before,
rather than after dialysis when the environment is less high Kt/Vurea values, BP control, LVH, and survival [33].
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Management of Renal Failure in Europe, XXII, 1991. NephrolTherefore, adequate dialysis dose delivery and strict BP
Dial Transplant 10(Suppl 5):S12, 1995
control could improve the otherwise poor cardiovascular 8. Mailloux LU, Haley WE: Hypertension in the ESRD patient:
Pathophysiology, therapy, outcomes, and future directions. Am Jprognosis and the overall survival of uremic patients.
Kidney Dis 32:705–719, 1998Actuarial survival time of patients with LVH in our cen-
9. Harnett JD, Parfrey PS, Griffiths SM, Gault MH, Barre P,
ter is approximately 58% after five years (unpublished Guttmann RD: Left ventricular hypertrophy in end-stage renal
disease. Nephron 48:107–115, 1988data). Most likely this percentage will increase in the
10. Cannella G, Paoletti E, Delfino R, Peloso GC, Molinari S,near future if we are able to deal with the prevalence
Traverso GB: Regression of left ventricular hypertrophy in hyper-
and severity of arterial hypertension more effectively. tensive dialyzed uremic patients on long-term antihypertensive
therapy. Kidney Int 44:881–886, 1993On the basis of the JNC VI criteria [14], approximately
11. Cannella G, Lacanna G, Sandrini M, Gaggiotti M, Nordio G,65% of the patients in the present study had arterial
Movilli E, Mombelloni S, Visioli O, Maiorca R: Reversal of
hypertension or were being treated with antihyperten- left ventricular hypertrophy following recombinant human eryth-
ropoietin treatment of anaemic dialysed uraemic patients. Nephrolsive drugs. This figure compares well with recent reports
Dial Transplant 6:31–37, 1991on larger series of dialyzed uremic patients both in Eu-
12. Cannella G, Paoletti E, Delfino R, Peloso GC, Rolla D,
rope and in the United States [8, 34, 35]. However, it Molinari S: Prolonged therapy with ACE inhibitors induces a
regression of left ventricular hypertrophy of dialyzed uremic pa-stands in poor contrast with the studies by French au-
tients independently from hypotensive effects. Am J Kidney Disthors [33], who reported excellent BP data, although
30:659–664, 1997
combined with persistent LVH, for uremic patients un- 13. Cannella G, Paoletti E, Barocci S, Massarino F, Delfino R,
Ravera G, Dimaio G, Nocera A, Patrone P, Rolla D: Angioten-dergoing long-lasting dialysis treatment (abstract; Luik
sin-converting enzyme gene polymorphism and reversibility of ure-et al, J Am Soc Nephrol 5:521, 1994).
mic left ventricular hypertrophy following long-term antihyperten-
Requests for dialysis treatment are quickly increasing sive therapy. Kidney Int 54:618–626, 1998
14. The Sixth Report of the Joint National Committee on preven-worldwide, thus imposing short-lasting, poorly flexible
tion, detection evaluation, and treatment of high blood pres-dialysis schedules in order to comply with these demands.
sure. Arch Intern Med 157:2413–2446, 1997
Furthermore, long-hour dialysis schedules would hardly 15. Staessen JA, Bieniaszewski L, O’Brien ET, Fagard R: What is
normal blood pressure on ambulatory monitoring? Nephrol Dialbe acceptable by most of our patients. Our study results
Transplant 11:241–245, 1996suggest that the potential improvement in our current
16. Staessen JA, Bieniaszewski L, O’Brien E, Gosse P, Hayashi H,
approach to arterial hypertension might still go far Imai Y, Kawasaki T, Otsuka K, Palatini P, Thijs L, Fagard R:
Nocturnal blood pressure fall on ambulatory monitoring in a largeenough without having to resort to difficult to adopt
international database. Hypertension 29:30–39, 1997dialysis procedures.
17. Sullivan J, Prewitt R, Ratts T, Josephs JA, Connor MJ: Hemo-
dynamic characteristics of sodium sensitive human subjects. Hyper-
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